The Patent Finder

Intellect Neurosciences Inc.

Also on record
Records under this name other than patents Intellect Neurosciences Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 9 of 9 · Back to Intellect Neurosciences Inc.

PatentTitleStatus Expires Confidence
US 8,703,137Treatment of Tauopathies
Formerly held
In force
 · High confidence
In forceHigh confidence
US 6,274,615Method for delaying the onset of alheimer's disease and for treatment or delaying the onset of other amyloidosis-related diseases/disorders
Term ended
Term ended Mar 25, 2019 · From the USPTO record
Term endedTerm ended Mar 25, 2019From the USPTO record
US 6,395,768Uses for indole-3-propionic acids and salts and esters thereof
Term ended
Term ended Feb 23, 2019 · From the USPTO record
Term endedTerm ended Feb 23, 2019From the USPTO record
US 7,807,157Monoclonal Antibodies and Use Thereof
Lapsed on the fee record
Ended Oct 5, 2018 · High confidence
Lapsed on the fee recordEnded Oct 5, 2018High confidence
US 8,173,127Specific Antibodies to Amyloid Beta Peptide, Pharmaceutical Compositions and Methods of Use Thereof
Term ended
Term ended Apr 15, 2018 · Medium confidence
Term endedTerm ended Apr 15, 2018Medium confidence
US 8,697,076Antibodies Selective for Pathological Tau Dimers and Prefibrillar Pathological Tau Oligomers and Their Uses in Treatment, Diagnosis and Monitoring of Tauopathies
Lapsed on the fee record
Ended Apr 15, 2018 · High confidence
Lapsed on the fee recordEnded Apr 15, 2018High confidence
US 8,338,379Monoclonal antibody and use thereof
Lapsed on the fee record
Ended Dec 25, 2016 · From the USPTO record
Lapsed on the fee recordEnded Dec 25, 2016From the USPTO record
US 7,901,689Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies
Lapsed on the fee record
Ended Mar 8, 2015 · From the USPTO record
Lapsed on the fee recordEnded Mar 8, 2015From the USPTO record
US 5,958,964Use of melatonin to prevent cytotoxic effects of amyloid beta protein
Term ended
Term ended no later than Sep 28, 2019 · Low confidence
Term endedTerm ended no later than Sep 28, 2019Low confidence
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited